ADMA Biologics (ADMA) 10-Q2023 Q2 Quarterly report

Filed: 9 Aug 23, 5:05pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: advisory, bore, broker, coupled, exfiltrated, external, GMP, hypothetical, inaccessible, IndexADMA, noteholder, original, prudent, restore, restored, root, subside, theoretically, unfavorable, unfavorably, week

Removed: Caligan, goal, NWQ, opened, professional, Pvt, track

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ADMA transcripts

ADMA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian Lenz, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2023	By:	/s/ Brian Lenz
	Name:	Brian Lenz
	Title:	Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.